Gilead R&D chief William Lee to retire as Amgen I/O vet Flavius Martin takes the reins in April
Longtime Gilead R&D chief William Lee is hanging up his cleats as the big biotech brings in a new face.
Lee will retire in just over a couple weeks on April 12, Gilead announced Friday morning. His replacement will be Flavius Martin, coming over from Amgen where he led research for their oncology, inflammation and cardiometabolic departments. Martin was also the site head for Amgen South San Francisco.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 107,000+ biopharma pros reading Endpoints daily — and it's free.